Pharmacoresistant seizures and IDH mutation in low-grade gliomas.
Carlos Eduardo CorreiaYoshie UmemuraJessica R FlynnAnne S ReinerEdward K AvilaPublished in: Neuro-oncology advances (2021)
22% of the IDH-mutated patients developed pharmacoresistant seizures, compared to 12% of the IDH wild-type tumors. The likelihood of developing pharmacoresistant seizures in patients with LGG-related epilepsy is independent to IDH mutation status, however, IDH-mutated tumors were approximately twice as likely to experience LGG-related pharmacoresistant seizures.